Promising results in AcouSort’s latest feasibility study with Instrumentation Laboratory
AcouSort has finalized the recent feasibility project with Instrumentation Laboratory (IL) concerning generation of blood plasma aiming to expand the use of AcouSort’s technology in additional IL product lines. The project results have been very promising, lining up for additional feasibility studies addressing blood-plasma separation together with IL.
– We are very pleased by the successful execution of the latest project together with IL and by the results generated within the project showing significant potential. We have over the last years managed to further strengthen our close collaboration and are now looking forward to being able to continue adapting our technology to fit into other IL product lines. By successful executions of projects like this, we stay on the path towards entering new OEM collaborations, says AcouSorts CEO Torsten Freltoft.
The new project was based on the successful collaboration between AcouSort and IL over the past years and is an important step in implementing AcouSort’s strategy becoming the preferred provider of OEM components for blood separation and expanding the product portfolio. With the promising results from the recently finalized project, it is expected to initiate further collaboration projects already later this year.
In recent years, AcouSort has had six collaborative projects with IL concerning the development and adaptation of AcouSort's technology for use in the company's products. In the diagnostics sector, IL is a world-leading international company with several product categories focusing on patient-centered blood diagnostics.
For further information on AcouSort, please contact:
Torsten Freltoft, CEO
Telephone: +45 2045 0854
E-mail: torsten.freltoft@acousort.com
About AcouSort
AcouSort AB (corporate registration number 556824-1037) is an innovative technology company focusing on developing products and solutions for integrated preparation of biological samples. With the help of sound waves, the company's products can separate blood cells, concentrate, purify and stain cells, exosomes and bacteria from biological samples. The technology of the company's products is acoustofluidics, where sound waves and microfluidics enable automated handling of samples in a range of application areas, from research on new biomarkers to the development of new diagnostic systems for near-patient testing – so-called Point-of Care (POC) systems. The company's commercialization strategy is based on the already proven business model of providing separation modules to diagnostic system manufacturers for integrated sample preparation as well as to continue the commercialization of the company's research instruments. With the help of the company's products and development of point-of-care tests, new diagnostic systems and treatments are enabled, addressing some of the most challenging disease areas of our time: cancer, infectious diseases and cardiovascular diseases.